FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule
News
The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication can ... Read more